SPY324.78+2.14 0.66%
DIA268.68+1.10 0.41%
IXIC10,752.63+119.64 1.13%

REGENXBIO Announces Dosing Of First Patient In Phase II AAVIATE Trial Of RGX-314 For The Treatment Of Wet AMD Using Suprachoroidal Delivery

ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ --REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its

· 09/09/2020 07:10

ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ --REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV®Technology Platform, today announced that the first patient has been dosed in the AAVIATE trial, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjectorfor the treatment of wet age-related macular degeneration (wet AMD). The Company expects to report interim data from the first cohort of this trial by the end of 2020.